TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two ...

WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company’s participation are as follows:     Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference ma ...

WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company’s participation are as follows: Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be ...

Core Insights - The launch of Day One Biopharmaceuticals, Inc.'s Ojemda has become a significant topic of discussion, particularly as the company's developmental efforts are expected to gain momentum in 2026 [1] Company Developments - Day One Biopharmaceuticals is focusing on the development of Ojemda, which is anticipated to be a key product for the company [1] Market Context - The commentary surrounding Day One Biopharmaceuticals reflects broader trends in the biotech sector, particularly regarding trading around significant events such as trial results and regulatory approvals [1]

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a distinguished global Contract Research Organ ...

Key Takeaways RCKT posted Q4 loss of 38 cents per share, beating estimates, while no revenues were reported.Rocket Pharmaceuticals' resubmitted BLA for Kresladi in LAD-I faces an FDA decision on March 28, 2026.RCKT expects cash runway into Q2 2027 as the RP-A501 study in Danon disease resumes in H1 2026.Rocket Pharmaceuticals (RCKT) incurred a loss of 38 cents per share in the fourth quarter of 2025, which was narrower than the Zacks Consensus Estimate of a loss of 42 cents. In the year-ago quarter, the com ...

Financial Overview - Oryzon Genomics reported a strong cash position of $33.3 million (€28.4 million) at the end of 2025, following a financial turnaround with over $60 million secured in the first half of 2025 [4][14]. - Research and development (R&D) expenses for Q4 2025 were $5.2 million, totaling $14.8 million for the year, compared to $2.1 million and $8.7 million in the same periods of 2024 [12]. - General and administrative expenses were $1.7 million for Q4 2025 and $5.6 million for the full year, up from $0.9 million and $3.7 million in 2024 [12]. - The net loss for Q4 2025 was $2.1 million, with a total net loss of $6.7 million for the year, compared to losses of $1.1 million and $4.6 million in 2024 [13][14]. Oncology Developments - Iadademstat, Oryzon's lead oncology program, is currently involved in seven ongoing trials, with six sponsored by the National Cancer Institute (NCI) or leading U.S. institutions [4][6]. - The drug has shown a 100% overall response rate (ORR) in first-line acute myeloid leukemia (AML) trials, with no dose-limiting toxicities reported [4][8]. - Preliminary data from the ALICE-2 Phase Ib trial indicated a 100% ORR and 90% strict complete remission (CR) in newly diagnosed AML patients [8]. - A new Phase Ib trial of iadademstat in combination with immune checkpoint inhibitors and radiotherapy for extensive-stage small cell lung cancer (ES-SCLC) has commenced [8]. CNS Program Updates - Oryzon has appointed Dr. Rolando Gutierrez as Chief Medical Officer for CNS programs, enhancing its medical and regulatory capabilities [4][7]. - The company is preparing for a protocol resubmission to the FDA for the Phase III PORTICO-2 trial in aggression in Borderline Personality Disorder (BPD) [13]. - Oryzon is expanding its Phase IIb schizophrenia trial into additional EU countries and finalizing preparations for a new Phase II trial in aggression in autism spectrum disorder (ASD) [7][13]. Intellectual Property and Future Trials - Oryzon has strengthened its intellectual property protection for iadademstat, with a patent application granted in Japan, expected to remain in force until at least 2040 [9]. - The company plans to initiate a clinical trial for iadademstat in essential thrombocythemia (ET) following EMA approval [8]. - Oryzon's earlier stage program, ORY-4001, a selective HDAC6 inhibitor, is progressing through IND enabling studies for neurological diseases [11].

With a market cap of $124.4 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy. Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Bristol-Myers Squibb fi ...

Company Overview - Structure Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative oral therapeutics for chronic diseases, particularly targeting significant unmet medical needs [2][3] - The company specializes in G-protein-coupled receptor (GPCR) drug discovery, with a pipeline led by GSBR-1290 aimed at treating type-2 diabetes and obesity, as well as candidates for pulmonary and cardiovascular diseases [2] Financial Performance - As of the end of 2025, Structure Therapeutics reported a net loss of $141.2 million, with research expenditures reaching $225.3 million to advance its GLP-1 franchise, which is typical for companies preparing for late-stage trials [9] - The company ended 2025 with $1.4 billion in cash and investments, which is expected to fund operations through the end of 2028 [8] Stock Performance - Structure Therapeutics' shares were priced at $71.41 as of February 17, 2026, reflecting a 214.3% increase over the past year, significantly outperforming the S&P 500 by 180.87 percentage points [4] - Casdin Capital sold 380,000 shares of Structure Therapeutics during the fourth quarter, valued at approximately $15.52 million based on the average share price for that period [5][6] Clinical Developments - The company reported promising data from its Phase 2 ACCESS programs, showing placebo-adjusted weight loss of up to 15.3% at 36 weeks with higher doses of aleniglipron, with no plateau observed [8] - A 44-week readout is anticipated in the first quarter of 2026, and the initiation of Phase 3 trials is planned for the second half of 2026 [8] Market Position - Structure Therapeutics aims to provide differentiated treatment options that enhance both efficacy and patient convenience, positioning itself competitively within the evolving biopharmaceutical landscape [1]

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months Early signals of functional and structural improvement observed at one month and three months12-letter BCVA gain and 23% CST reduction observed in the treated eye at three monthsFull cohort data expected in mid-year 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Com ...